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Non-motor symptoms, including psychiatric disorders, are increasingly recognized as a
major challenge in the treatment of Parkinson’s disease (PD). These ailments, which
often appear in the early stage of the disease, affect a large number of patients and
are only partly resolved by conventional antiparkinsonian medications, such as L-DOPA.
Here, we investigated non-motor symptoms of PD in a mouse model based on bilateral
injection of the toxin 6-hydroxydopamine (6-OHDA) in the dorsal striatum. This model
presented only subtle gait modifications, which did not affect horizontal motor activity
in the open-field test. Bilateral 6-OHDA lesion also impaired olfactory discrimination,
in line with the anosmia typically observed in early stage parkinsonism. The effect of
6-OHDA was then examined for mood-related dysfunctions. Lesioned mice showed
increased immobility in the forced swim test and tail suspension test, two behavioral
paradigms of depression. Moreover, the lesion exerted anxiogenic effects, as shown
by reduced time spent in the open arms, in the elevated plus maze test, and by
increased thigmotaxis in the open-field test. L-DOPA did not modify depressive- and
anxiety-like behaviors, which were instead counteracted by the dopamine D2/D3 receptor
agonist, pramipexole. Reboxetine, a noradrenaline reuptake inhibitor, was also able to
revert the depressive and anxiogenic effects produced by the lesion with 6-OHDA.
Interestingly, pre-treatment with desipramine prior to injection of 6-OHDA, which is
commonly used to preserve noradrenaline neurons, did not modify the effect of the
lesion on depressive- and anxiety-like behaviors. Thus, in the present model, mood-related
conditions are independent of the reduction of noradrenaline caused by 6-OHDA. Based
on these findings we propose that the anti-depressive and anxiolytic action of reboxetine
is mediated by promoting dopamine transmission through blockade of dopamine uptake
from residual noradrenergic terminals.
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INTRODUCTION
Parkinson’s disease (PD) is classically defined by the progres-
sive degeneration of the dopaminergic nigro-striatal pathway and
by the emergence of rigidity, tremor, and bradykinesia (Braak
et al., 2003; Jankovic, 2008). However, PD is also accompa-
nied by non-motor symptoms, including olfactory loss, cognitive
decline, depression and anxiety, which frequently appear in the
early stages or even during the pre-motor phase of the disease
(Ward et al., 1983; Aarsland et al., 2004; Chaudhuri and Schapira,
2009). Psychiatric symptoms have been related to monoaminer-
gic deficits within components of the limbic system implicated in
emotional and affective functions. In fact, the progressive death
of midbrain dopaminergic neurons in PD is paralleled by the con-
comitant degeneration of noradrenergic and serotonergic systems
(Halliday et al., 1990; Braak et al., 2003; Remy et al., 2005; Kish
et al., 2008; Frisina et al., 2009).
Although L-DOPA remains the gold standard therapy for the
motor symptoms of PD, its efficacy onmood-related dysfunctions
is limited and its chronic administration correlates with the
emergence of depression and anxiety (Damasio et al., 1971;Marsh
and Markham, 1973; Vazquez et al., 1993; Choi et al., 2000; Kim
et al., 2009; Negre-Pages et al., 2010; Eskow Jaunarajs et al., 2011).
In addition, the use of L-DOPA is complicated by the devel-
opment of motor side effects such as dyskinesia (Obeso et al.,
2000). In this context, drugs acting preferentially on dopamineD2
receptors (D2Rs) and D3 receptors (D3Rs) represent a potential
alternative (Hametner et al., 2012). For instance, the D2R/D3R
agonist, pramipexole, has been shown to reduce depression and
anxiety in clinical trials (Leentjens et al., 2009; Barone et al.,
2010).
Common antidepressant agents, such as noradrenaline and
serotonin reuptake inhibitors, have also been tested in parkinso-
nian patients. Tricyclic antidepressants acting on noradrenaline
reuptake, such as desipramine and reboxetine, as well as citalo-
pram, a selective serotonin reuptake inhibitor, reduce depression
associated to PD (Lemke, 2002; Devos et al., 2008). Nortriptyline,
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which blocks noradrenaline and serotonin reuptake, is also able to
reduce depression in PD patients (Menza et al., 2009). However,
mood disorders in PD are still considered difficult to treat, possi-
bly due to the low dosage of appropriate medications normally
employed to avoid worsening of motor symptoms (Weintraub
et al., 2003). In this regard, the development of reliable preclin-
ical models reproducing the non-motor symptoms of parkinso-
nian patients is critical to further characterize the mechanisms
implicated in these conditions and to test novel therapeutic
strategies.
We have previously described a cognitive deficit in a mouse
model of PD generated by partial bilateral lesion of the cate-
cholamine system, achieved with intra-striatal injections of 6-
hydroxydopamine (6-OHDA). This procedure decreases tyrosine
hydroxylase (TH) immunoreactivity, as well as dopamine and
noradrenaline levels, in the striatum and hippocampus. These
effects are paralleled by a reduction of TH-positive cells in
the substantia nigra pars compacta and in the locus coeruleus
(Bonito-Oliva et al., 2014). Here, we show that the same exper-
imental model displays a series of anomalies associated to parkin-
sonism, including gait impairment and olfactory deficit. Notably,
this model also reproduces mood dysfunctions analogous to those
observed in PD patients. Various drugs interfering with dopamin-
ergic and noradrenergic transmission were tested for their ability
to counteract these latter conditions.
MATERIALS AND METHODS
ANIMALS
Male C57BL/6J mice (25–30 g; Taconic, Tornbjerg, Denmark)
were housed under a 12 h light-dark cycle with food and water
ad libitum. Experiments were carried out during the light phase,
in accordance with the guidelines of Research Ethics Committee
of Karolinska Institutet, Swedish Animal Welfare Agency and
European Communities Council Directive 86/609/EEC.
DRUGS
The following drugs were used: benserazide hydrochloride,
3,4-dihydroxy-l-phenylalanine (L-DOPA), 6-hydroxydopamine
hydrochloride (6-OHDA) and desipramine hydrochloride
(Sigma-Aldrich, St. Louis, MO, USA), pramipexole dihydrochlo-
ride (Tocris, Bristol, UK) and reboxetine mesylate (Abcam
Biochemicals, Cambridge, UK). 6-OHDA was dissolved in
saline containing 0.02% ascorbic acid and locally injected in the
brain. Desipramine (25mg/kg, i.p.), pramipexole (0.6mg/kg,
s.c.), reboxetine (20mg/kg, i.p.) and L-DOPA [10mg/kg, i.p.;
administered together with the peripheral DOPA decarboxylase
inhibitor, benserazide (7.5mg/kg)] were dissolved in saline. All
drugs were injected in a volume of 10ml/kg. Desipramine was
administered 30min before the injection of 6-OHDA. The other
drugs were administered for four consecutive days preceding the
experiment. The animals were tested 30min after the last drug
administration.
6-OHDA LESION
Mice were anesthetized with a mixture of Hypnorm®
(VetaPharma Ltd, Leed, UK), midazolam (5mg/ml) (Hameln
Pharmaceuticals GmbH, Hameln, Germany) and water (1:1:2
in a volume of 10ml/kg) and mounted in a stereotaxic frame
(David Kopf Instruments, Tujunga, CA, USA). Each mouse
received a bilateral injection of 1μl of 6-OHDA (4μg/μl)
into the dorsal-lateral striatum, according to the following
coordinates (mm) (Franklin and Paxinos, 1997): antero-
posterior +0.6, medio-lateral ±2.2, and dorso-ventral −3.2.
Control sham-lesioned (sham) mice were injected with the
same volume of vehicle (0.9% saline and 0.02% ascorbic
acid). After surgery, the animals were allowed to recover for
3 weeks.
EXPERIMENTAL PLAN
A total of 154 sham and 6-OHDA-lesioned mice were randomly
assigned to the different experimental groups and examined in
batteries of behavioral tests, which were performed sequentially
according to their increasing invasiveness (i.e., gait analysis, open
field and tail suspension; or odor discrimination, elevated plus
maze and forced swim test). Each test was separated by a rest-
ing period of 7–10 days. Additional groups of sham and 6-OHDA
lesioned mice were used to evaluate the effects of drugs (i.e., L-
DOPA, pramipexole, desipramine and reboxetine) in the elevated
plus maze and forced swim test. Four percent of the animals ini-
tially involved in the study died during the post-operatory phase,
and 5% of the animals injected with 6-OHDAwere excluded from




The pattern of motor coordination of sham and 6-OHDA-
lesioned mice was examined using ventral plane videography
(Amende et al., 2005; Hampton and Amende, 2010). The appara-
tus consisted of a motor-driven transparent treadmill belt (Exer
Gait XL, Columbus Instruments, USA) and a high-speed dig-
ital video camera (100 fps) to record the ventral view of the
treadmill belt, as reflected by an angled mirror. An adjustable
compartment (17×5 cm) was mounted over the treadmill belt
to maintain the mouse in the view of the camera, limit lateral
movements and reduce parallax errors. All tested mice had simi-
lar body lengths (mean snout-vent size 8 ± 0.6 cm) and were first
habituated to a still treadmill for 3min, followed by 1min dur-
ing which the speed was progressively increased from 0 to 17 cm/s
(Heglund and Taylor, 1988; Leblond et al., 2003). Once the test-
ing speed was achieved gait was recorded during three 20 s trials
separated by 1min inter-trials periods. The contacts made with
the treadmill by each individual paw were determined using the
TreadScan software (Treadscan 4.0, Clever Sys, Inc., Reston, VA,
USA). For each animal at least 20 steps/paw were analyzed. The
following standard gait parameters were measured: stride dura-
tion (time separating two consecutive contacts with the treadmill
made with the same paw), stance time (portion of the stride dur-
ing which the paw is in contact with the treadmill) and swing
time (portion of the stride during which the paw is not in con-
tact with the treadmill). All measurements were averaged. The
time during which the animals ran to the front, drifted back-
ward on the belt, or explored the chamber were excluded from the
analysis.
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Olfactory analysis
Olfaction was measured using a modified version of the olfactory
habituation/dishabituation test, as previously described (Wrenn
et al., 2003; Crawley et al., 2007; Stack et al., 2008; Yang and
Crawley, 2009). On the test day, each mouse was habituated for
2 h to a bedding-supplied home cage (30 × 15× 15 cm). Next,
a dry cotton tipped swab was placed in the cage for 30min. At
the end of this habituation phase, the animal was exposed to a
sequence of five odors delivered through cotton swabs, accord-
ing to the following sequence: water, almond flavor, citrus flavor,
social odor 1(social1), social odor 2(social2). The almond and
citrus odors were prepared by diluting almond and citrus fla-
vors (Dr. Oetker) in distilled water (1:600); each social odor was
obtained by pooling the urine of two adult male mice. Each
odor was presented for three consecutive 2min periods, sepa-
rated by approximately 30 s inter-trials. For every exposure, the
cotton swab was freshly prepared with a fixed amount of solu-
tion (5 and 4μl for non-social and social odors, respectively).
The test was video-recorded and exploratory activity (time dur-
ing which the mouse nose was in contact with the cotton swab,
or directed toward it at a distance ≤2 cm) was measured by an
observer blind to the experimental groups. This protocol allows
to determine the habituation to a specific odor, indicated by the
progressive decreased in exploration time for the same odor dur-
ing the three presentations, and the dishabituation, measured as
increased exploration time for a new odor, which is an index
of the ability to discriminate olfactory novelty (Silverman et al.,
2011).
Forced swim test
In the forced swim test, each mouse was placed in a glass cylinder
(25 cm in height and 13 cm in diameter), filled up to 15 cm with
tap water at a temperature of 22◦C and let swim for 10min. At the
end of the test, the mouse was removed from the cylinder, gently
dried and placed in the home cage under warm light, for 10min.
The swimming behavior of each animal was video-recorded and
analyzed by an observer blind to the experimental groups. The
immobility time (defined as the time spent by the mouse floating,
with only minimal movements to keep the head above the water
surface) was measured and considered as an index of depression
(Castagne et al., 2009).
Tail suspension test
In the tail suspension test, mice were suspended by the tail, with
adhesive tape, on a metal rod installed 30 cm above the plane
of a laboratory bench and left in this position for 6min. The
behavior of each mouse was video-recorded and analyzed by an
observer blind to the experimental groups. The immobility time
(defined as the time during which the animal was hanging pas-
sively and motionless) was measured and considered as an index
of depression (Steru et al., 1985).
Elevated plus maze test
The elevated plus maze apparatus was composed of four black
plastic arms, arranged as a cross, located 55 cm above the plane
of a laboratory bench and illuminated by a 60w lamp located
above the apparatus. Two close arms, opposite to each other were
enclosed by lateral walls (50 × 6× 40 cm), whereas the other two
open arms were without walls (50 × 6× 0.75 cm); the close and
open arms delimited a small squared area (6 × 6 cm) called cen-
ter. Each mouse was placed into the center of the maze, facing one
of the two open arms, and its behavior was video-recorded for
5min. The time spent by the mice in each of the three compart-
ments (open, close, center) was measured by an observer blind to
the experimental groups. The propensity to avoid the open arms
is considered as an index of anxiety (Lister, 1987).
Open field test and thigmotaxis
Thigmotaxis was determined in an open field box (40 × 40×
40 cm), virtually divided in a peripheral and a central zone of
equivalent area. Each mouse was allowed to explore the appara-
tus for 15min and its behavior was recorded by a video camera
connected to an automated tracking system (BIOBSERVEGmbH,
Germany). In this test, the preferential exploration of the periph-
eral zone of the open field is considered an index of anxiety
(Simon et al., 1994).
WESTERN BLOTTING
At the end of each test battery, mice were sacrificed by decap-
itation, left and right striata were dissected out, sonicated in
750μl of 1% SDS and boiled for 10min. TH-immunoreactivity
was determined by Western blotting as previously described
(Bonito-Oliva et al., 2014). Briefly, aliquots (5μl) from son-
icated striata were used for protein quantification with the
BCA assay kit (Pierce, Rockford, IL, USA). Equal amounts
of protein (5μg) for each sample were loaded onto 10%
polyacrylamide gels. Proteins were separated by SDS-PAGE
and transferred overnight to polyvinylidene difluoride mem-
branes (GE Healthcare, Little Chalfont, UK). The membranes
were immunoblotted using a mouse anti-TH antibody (1:3000,
Chemicon International, Temecula, CA, USA), and then incu-
bated in horseradish peroxidase-conjugated secondary anti-
mouse antibody (1:30000). The protein signal was visualized by
ECL (Pierce, Rockford, IL, USA) and quantified using Quantity
One software (Bio-Rad). The levels of TH were expressed as per-
cent of those in sham striatum and used to assess the effectiveness
of the lesion.
STATISTICAL ANALYSIS
Data were analyzed using One-Way ANOVA and post-hoc com-
parisons between groups were made using the Fisher’s or
Sidak-Bonferroni test. Student’s t-test with equal variances was
used to analyze experiments with two groups. For the olfac-
tory habituation/dishabituation tests, data were analyzed using
repeated measures ANOVA followed by Newman-Keuls post-hoc
comparison test.
RESULTS
EFFECT OF PARTIAL 6-OHDA LESION ON STRIATAL TH
We have previously shown that the protocol of 6-OHDA
lesion utilized in this study produces a partial decrease in TH
immunoreactivity in the striatum (Bonito-Oliva et al., 2014). In
line with this result, Western blotting quantification showed a
reduction of striatal TH immunoreactivity ranging from 63 to
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74%. The animals that did not match this criterion (5% of the
mice injected with 6-OHDA) were excluded from the behavioral
analysis.
PARTIAL BILATERAL 6-OHDA LESION DISRUPTS STEP CYCLE
REGULARITY BY REDUCING HINDLIMB STANCE
In line with previous work indicating the limited effect of the par-
tial 6-OHDA lesion onmotor function (Bonito-Oliva et al., 2014),
lesioned mice did not differ from shammice with regard to stride
length (distance between two successive footfalls of the same
paw), stride frequency and stride duration (time lag between
two successive touches down of the reference limb) (Table 1).
Moreover, alignment of the body axis to the direction of the
movement, body swing, and track width (i.e., measure of the
distance between the two front or hind paws) were similar in
6-OHDA-lesioned and sham mice (Table 1).
6-OHDA-lesioned mice were then analyzed for step cycle
regularity, which indicates the frequency of correct step cycles
(i.e., fully coordinated motion in which each paw is placed
on time every four times) during movement (Redondo-Castro
et al., 2013). Sham and 6-OHDA-lesioned mice performed the
same number of step cycles during the test (98 ± 9 and 80
± 7 step cycles, respectively). However, as shown in the ven-
tral videogram (Figure 1A), lesioned mice differ from sham
mice with regard to the way in which they bring their paws
in contact with the ground, which results in a significant
impairment in step-cycle regularity (p < 0.0001, Student’s t-test)
(Figure 1B).
Mice were further analyzed for inter-limb coordination by
examining coupling of the homolateral limbs (i.e., limbs on the
right or left side), coupling of the homologous limbs (i.e., fore-
limbs or hindlimbs) and coupling of the diagonal limbs (i.e., right
forelimb with left hindlimb and vice versa). Whereas no differ-
ences were observed in the first two parameters (data not shown),
diagonal coupling was out of phase in lesioned mice. Sham mice
showed a coupling interval (i.e., percent of time during which the
diagonal limbs contact the ground at the same time) over 75%
(78.6 ± 1.4%), which is in line with what has been previously
described in C57BL/6 mice (Leblond et al., 2003) (Figure 1C).
Table 1 | Summary of gait parameters in sham and 6-OHDA-lesioned
mice.
Sham 6-OHDA-lesioned
Front track width (mm) 10.65±0.63 10.24±0.83
Hind track width (mm) 18.85±1.02 19.22±1.45
Stride length (mm) 46.35±1.11 50.08±1.23
Normal stride frequency (Hz) 3.67±0.07 3.52±0.05
Stride duration (ms) 223.0±7.1 232.5±6.3
% Forelimb swing time 45.96±1.44 47.70±1.42
% Hindlimb swing time 44.41±1.57 51.70±2.08*
Twenty-two sham mice and 17 6-OHDA-lesioned mice were examined on a
treadmill set at a speed of 17 cm/s. For each animal, data were collected from
20 to 25 strides and averaged. Data are expressed as mean ± s.e.m. *p < 0.05
vs. Sham group, Student’s t-test.
This parameter was reduced to 72.7 ± 2.4% in lesioned mice
(p < 0.05, Student’s t-test) (Figure 1C). In line with these gait
abnormalities, stride cycle analysis of 6-OHDA-lesioned mice
revealed increased hindlimb swing time (cf. Table 1) and shorter
stance (time with the limb in contact with the ground), affecting
selectively the hindlimbs (p < 0.01, Student’s t-test) (Figure 1D).
Note that for all the above-mentioned measures, no differences
were found for gait variability (standard deviation) and coeffi-
cient of variability (calculated as 100 × standard deviation/mean
value).
REDUCED OLFACTORY DISCRIMINATION IN 6-OHDA-LESIONED MICE
Loss of olfaction (anosmia) is among the earliest manifestations
of PD. This disturbance affects most patients and typically pre-
cedes the motor symptoms of the disease (Ward et al., 1983; Doty
et al., 1988; Braak and Del Tredici, 2009). Anosmia was examined
by comparing the olfactory discriminative ability of mice with
partial 6-OHDA lesion with that of sham mice. Specifically, we
measured the progressive decrease in exploration during repeated
presentations of the same odor (habituation), as well as the
tendency to explore for a longer period of time a new odor (disha-
bituation) (Woodley and Baum, 2003). Previous work showed
that the 6-OHDA lesion utilized in this study does not affect
exploratory activity (Bonito-Oliva et al., 2014). In line with this
observation, lesioned mice showed normal baseline exploratory
activity for the neutral stimulus water (Figure 2). Therefore, in
this test, the exploratory activity was considered an index of
attractiveness to the odor itself (Macknin et al., 2004; Crawley
et al., 2007).
Sham and 6-OHDA-lesioned mice showed olfactory habit-
uation for all odors tested, as indicated by the decreases in
exploration time displayed by the two groups of mice during the
3 consecutive presentations of the same odor (Figure 2, upper
panel). One-Way ANOVA with repeated measure (trial) indicated
a progressive reduction in exploration time for each odor in
sham [water F(2, 5) = 6.503, p < 0.05; almond F(2, 7) = 4.643,
p < 0.05; lime F(2, 7) = 11.015, p < 0.01; social1 F(2, 7) = 13.957,
p < 0.01; social2 F(2, 7) = 19.499, p < 0.01] and in 6-OHDA-
lesionedmice [water F(2, 10) = 7.893, p < 0.01; almond F(2, 10) =
11.025, p < 0.01; lime F(2, 10) = 6.009, p < 0.05; social1
F(2, 10) = 32.245, p < 0.0001; social2 F(2, 10) = 4.181, p < 0.05].
We also analyzed the effect of the 6-OHDA lesion on the habit-
uation profile for each odor. Two-way ANOVA with repeated
measure (trial) revealed a significant lesion effect for lime
[F(1, 19) = 12.482, p < 0.01] and for social2 [F(1, 19) = 42.061,
p < 0.0001] and a significant lesion × trial interaction in the
case of odor social2 [F(2, 38) = 8.278, p < 0.01; p < 0.0001 for all
trials, Newman-Keuls post-hoc].
The ability of the mice to detect olfactory novelty (disha-
bituation) was evaluated based on the increase in time spent
exploring the first swab of a new odor (Figure 2, upper panel).
For each odor replacement, data were analyzed by One-Way
ANOVA with repeated measure (trial) in sham [water to almond
F(1, 6) = 6.174, p < 0.05; almond to lime F(1, 8) = 20.420, p <
0.01, lime to social1 F(1, 8) = 64.442, p < 0.0001; social1 to
social2 F(1, 8) = 11.986, p < 0.01] and 6-OHDA-lesioned mice
[water to almond F(1, 11) = 12.896, p < 0.01, almond to lime
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FIGURE 1 | Disruption of step cycle regularity in 6-OHDA-lesioned
mice. Gait dynamics and pattern of motor coordination during locomotion
were analyzed in sham (n = 22) and 6-OHDA-lesioned (Lesioned) (n = 17)
mice. (A) Representative images of a complete step cycle (250ms),
shown in six consecutive frames taken every 50ms, performed by a sham
(upper) and a 6-OHDA-lesioned (bottom) mouse. (B) Bar graph showing the
regularity index (expressed as percentage of correct step sequences over
total number of step cycles) in sham and 6-OHDA-lesioned mice. (C) The
coupling interval (expressed in percent) of diagonal limbs for each sham
and 6-OHDA-lesioned mouse is represented in a circular graph, which
shows in phase or out of phase touches performed on the treadmill.
Individual circles represent the average phase value of each animal. The
dashed inner circle represents the cut off of significance. The length of the
green and red lines is proportional to the statistical significance and the
two circles connected to the lines represent the mean phase value of
sham (green) and 6-OHDA-lesioned (red) mice. (D) Bar graph showing the
relative contribution to the stride (expressed as percentage) of forelimb
stance (left) and hindlimb stance (right), in sham and 6-OHDA-lesioned
mice. Data are expressed as mean ± s.e.m. ∗∗∗p < 0.0001, ∗p < 0.01 vs.
sham mice, Student’s t-test.
F(1, 11) = 12.397, p < 0.01, lime to social1 F(1, 11) = 61.941, p <
0.0001, social1 to social2 not significant] (Figure 2). We then ana-
lyzed the effect of the 6-OHDA lesion on the dishabituation for
each odor replacement by Two-Way ANOVA with repeated mea-
sure (trial). We found a significant lesion× trial interaction when
the mice were exposed to a new odor within the same cate-
gory non-social: almond to lime [F(1, 19) = 6.949, p < 0.01] and
social: social1 to social2 [F(1, 19) = 39.65, p < 0.0001]. Notably,
no interaction effect was found when the animals were exposed
for the first time to a non-social (almond), or social (social1)
odor.
Finally, we analyzed the total time spent by the animals
exploring the three consecutive presentations of the same odor
(Figure 2, lower panels). Sham and 6-OHDA-lesioned mice dis-
played similar exploration time for water, almond and social1.
In contrast, 6-OHDA-lesioned mice showed decreased explo-
ration time for lime and social2 (p < 0.01 and p < 0.0001 vs.
sham-lesioned mice, respectively; Student’s t-test).
Altogether, these results indicated that the partial 6-OHDA
lesion causes an olfactory deficit, as indicated by the reduced
response of lesioned mice in the habituation/dishabituation test,
when presented with odor stimuli that belong to the same
category.
BILATERAL 6-OHDA LESION INDUCES DEPRESSION- AND
ANXIETY-LIKE BEHAVIORS IN THE MOUSE
The effect produced by partial 6-OHDA lesion on depressive-
like behavior was examined in the forced swim and tail
suspension tests (Castagne et al., 2009; Ginsberg et al.,
2012). We found that, in the forced swim test, 6-OHDA-
lesioned mice displayed a longer immobility time (considered
an index of depression) in comparison to sham mice (p <
0.0001, Student’s t-test) (Figure 3A). A similar difference was
observed when sham and 6-OHDA-lesioned mice were exam-
ined in the tail suspension test (p < 0.0001, Student’s t-test)
(Figure 3B).
Mice were then examined for anxiety-like behavior in the
elevated plus maze. During the 5min test, sham and 6-OHDA-
lesioned mice spent the same amount of time in the center of the
apparatus and showed a clear preference for the close arms over
the open arms (data not shown). However, this preference was
more pronounced in the lesioned mice, which spent significantly
less time in the open arms, as compared to sham mice (p < 0.01,
Student’s t-test) (Figure 4A).
The anxiety-like phenotype induced by the lesion was con-
firmed by testing the mice in the open field (Figures 4B,C).
In line with previous work, lesion with 6-OHDA did not
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FIGURE 2 | Reduced olfactory discrimination in 6-OHDA-lesioned
mice. The ability of sham (n = 9) and 6-OHDA-lesioned (Lesioned)
(n = 12) mice to recognize different odors was examined in the
habituation/dishabituation test. Exploratory activity was measured as
time (s) spent by the animals sniffing water- (control), or odor-wet
cotton swabs. The mice were exposed to three consecutive 2min
presentations of each odor, according to the following order: water,
non-social (almond, lime) and social (social1 and social2), with 30 s
intervals between each exposure. Lower panels show the total
exploration time (s) spent by sham and 6-OHDA-lesioned mice sniffing
individual odors (water, almond, lime, social1, social2). The gray
background indicates the second odor presented for each category
(non-social and social). Data are presented as mean ± s.e.m.
∗∗p < 0.01, ∗∗∗p < 0.0001 vs. sham mice, Student’s t-test.
affect horizontal motor activity, as indicated by similar dis-
tances covered by sham and 6-OHDA-lesioned mice during
the test (15min) (Figure 4B). However, 6-OHDA-lesioned mice
showed a pronounced increase in thigmotaxis when com-
pared to sham mice, as indicated by less time spent in
the center of the open field (p < 0.01, Student’s t-test) and
shorter distance covered in the center of the open field (p <
0.01, Student’s t-test) (Figure 4C). Taken together these data
demonstrate that, in the mouse, a partial catecholamine lesion
induced by 6-OHDA leads to behaviors indicative of affective
dysfunctions.
DEPRESSION- AND ANXIETY-LIKE BEHAVIORS INDUCED BY
BILATERAL 6-OHDA LESION ARE REVERTED BY PRAMIPEXOLE, BUT
NOT BY L-DOPA
We next examined the ability of L-DOPA and pramipexole,
two drugs commonly used to treat the motor symptoms of
PD, to revert the depression- and anxiety-like behaviors pro-
duced by bilateral 6-OHDA lesion. In the forced swim test,
four consecutive days of treatment with L-DOPA (10mg/kg)
did not reduce the immobility time produced by the lesion
(Figure 5A). In contrast, a similar treatment with pramipexole
(0.6mg/kg), a D2R/D3R agonist, reverted the depressive phe-
notype (Figure 5A). One-Way ANOVA indicated significant
treatment effect [F(3, 28) = 10.258, p < 0.0001] and Fisher’s
post-hoc comparison indicated a significant difference (p <
0.01) between 6-OHDA-lesioned mice treated with saline, or
pramipexole.
Similar results were obtained when the mice were tested in
the elevated plus maze. The animals did not show any treatment-
dependent difference in the time spent in the center of the appa-
ratus (data not shown). Importantly, L-DOPA did not counteract
the reduction in the time spent in the open arms caused by the
lesion with 6-OHDA (Figure 5B). Conversely, following admin-
istration of pramipexole the performance of lesioned mice was
undistinguishable from that of shammice, (Figure 5B). One-Way
ANOVA indicated a significant effect of the treatment [F(3, 23) =
23.286, p < 0.0001] and Fisher’s post-hoc comparison indicated
a significant difference (p < 0.0001) between 6-OHDA-lesioned
mice treated with saline, or pramipexole.
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FIGURE 3 | Depression-like phenotype in 6-OHDA-lesioned mice. Sham
and 6-OHDA-lesioned (Lesioned) mice were tested for depression-like
behavior in the forced swim test (A) and tail suspension test (B). Bar
graphs show the immobility time (s) of sham and 6-OHDA-lesioned mice,
during the forced swim test (A; test duration, 10min, sham n = 12,
lesioned n = 15) and the tail suspension test (B; test duration 6min, sham
n = 15, lesioned n = 12). Data are expressed as mean ± s.e.m.
∗∗∗p < 0.0001 vs. sham mice, Student’s t-test.
DEPRESSION- AND ANXIETY-LIKE BEHAVIORS INDUCED BY
BILATERAL 6-OHDA LESION ARE CORRECTED BY REBOXETINE, BUT
INDEPENDENT OF NORADRENALINE DEPLETION
We have previously shown that the lesion utilized in this study
induces a partial depletion of noradrenaline in striatum and
hippocampus (Bonito-Oliva et al., 2014). Therefore, we exam-
ined the effect produced by the selective noradrenaline reuptake
inhibitor, reboxetine. We found that four consecutive days of
treatment with reboxetine (20mg/kg) reverted the effects of the
lesion on both forced swim test (Figure 6A) and elevated plus
maze (Figure 6B). One-Way ANOVA indicated a significant effect
of the treatment [F(3, 43) = 14.439, p < 0.0001 for the forced
swim test and F(3, 43) = 16.204, p < 0.0001 for elevated plus
maze]. Fisher’s post-hoc comparison indicated a significant differ-
ence for both tests between 6-OHDA-lesioned mice treated with
saline, or reboxetine (p < 0.01 and p < 0.0001, respectively).
We further investigated the involvement of the noradren-
ergic innervation by pre-treating the mice with desipramine,
another selective noradrenaline reuptake inhibitor, prior to injec-
tion of 6-OHDA. This procedure preserves the noradrenergic
neurons, thereby limiting the lesion to the dopaminergic inner-
vation (Bonito-Oliva et al., 2014). Administration of desipramine
(25mg/kg), 30min prior to 6-OHDA, did not affect the ability
of the lesion to increase the immobility time in the forced swim
test (Figure 6A), or to reduce the time spent in the open arms, in
the elevated plus maze test (Figure 6B). This suggested that the
depletion of dopamine caused by 6-OHDA is sufficient to induce
affective-like symptoms.
DISCUSSION
There is ample evidence that PD is manifested not only as a motor
disorder, but also as a condition characterized by a variety of
non-motor symptoms, ranging from sleep disturbances and anos-
mia, to cognitive and psychiatric disorders. In this study we show
FIGURE 4 | Anxiety-like phenotype in 6-OHDA-lesioned mice. Sham and
6-OHDA-lesioned (Lesioned) mice were tested for anxiety-like behavior in
the elevated plus maze (A) and open field (B,C). (A) In the elevated plus
maze, the time spent in the open arms (% of the test duration) by sham
(n = 12) and 6-OHDA-lesioned mice (n = 15) mice, was measured during a
5min test. (B) In the open field, the total distance (m) covered by sham
(n = 11) and 6-OHDA-lesioned mice (n = 8) mice was measured, during a
15min test. (C) Thigmotaxis was evaluated in the open field by measuring
the time spent (% of total test duration) and the distance covered (% of
total distance covered) in the center of the apparatus (left and right panel,
respectively). Data are expressed as mean ± s.e.m. ∗∗p < 0.01 vs. sham
mice, Student’s t-test.
that a partial bilateral lesion of the dorsal striatum with 6-OHDA
results in a subtle impairment of gait dynamics, accompanied
by olfactory deficit, depression- and anxiety-like behavior. The
mild motor impairment indicates that this model reproduces a
relatively early stage of PD, which is in line with the partial reduc-
tion (70%) in dopamine and noradrenaline previously reported
(Bonito-Oliva et al., 2014).
Lesioned mice do not display any reduction in horizontal
motor activity and show normal stride length and frequency.
These results contrast with previous work in the 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD,
showing shorter stride length and increased stride frequency
(Fernagut et al., 2002; Amende et al., 2005), indicative of a more
pronounced motor impairment. However, a detailed analysis of
gait dynamics indicates that the lesion with 6-OHDA employed in
this study disrupts step coordination and that this impairment is
caused by reduced stance affecting the hindlimbs. This gait deficit
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FIGURE 5 | Effect of L-DOPA and pramipexole on depression- and
anxiety-like behaviors in 6-OHDA-lesioned mice. Sham, and
6-OHDA-lesioned mice treated for 4 days with saline, L-DOPA (10mg/kg), or
pramipexole (0.6mg/kg) were tested in (A) the forced swim test, or (B) the
elevated plus maze test. Bar graphs show the immobility time (s) during the
forced swim test (A; test duration, 10min) and the time spent in the open
arms (% of the test duration) during the elevated plus maze test (B; test
duration 5min). Data are expressed as mean ± s.e.m. (n = 4 − 7).
∗∗p < 0.01, ∗∗∗p < 0.0001 vs. sham mice, ##p < 0.01,### p < 0.0001 vs.
6-OHDA-lesioned mice treated with saline, One-Way ANOVA, followed by
Fisher post-hoc.
is in line with the variations in the stance phase observed in PD
patients (Ivkovic and Kurz, 2011) and may also be involved in
the reduced ability to stand on hindlimbs (rearing), previously
observed in the same mouse model (Bonito-Oliva et al., 2014).
Olfactory dysfunction is an early clinical sign in several neu-
rodegenerative disorders. In PD, the incidence of this symptom,
manifested as impairment in odor identification, threshold detec-
tion, and odor recognition memory, may even surpass that of
tremor (Doty et al., 1988; Mesholam et al., 1998). The onset of
olfactory deficit precedes the motor symptoms by several years
and is regarded as a strong predictor of risk for future PD
(Ross et al., 2008). The most prominent olfactory impairment
detected in the present model of PD pertains to the ability to
FIGURE 6 | Effect of noradrenaline reuptake inhibitors on anxiety- and
depression-like behaviors induced by 6-OHDA. Sham, and
6-OHDA-lesioned mice treated for 4 days with saline, or reboxetine
(20mg/kg). An additional group of mice (red) was pretreated with
desipramine (25mg/kg) prior to lesion with 6-OHDA. Bar graphs show the
immobility time (s) during the forced swim test (A; test duration, 10min)
and the time spent in the open arms (% of the test duration) during the
elevated plus maze test (B; test duration 5min). Data are expressed as
mean ± s.e.m. (n = 7 − 21).∗∗p < 0.01,∗∗∗ p < 0.0001, vs. sham mice,
##p < 0.01,### p < 0.0001 vs. 6-OHDA-lesioned mice treated with saline,
One-Way ANOVA, followed by Fisher post-hoc.
recognize an odor as novel. This deficit is limited to the dis-
crimination between odors belonging to the same category, i.e.,
non-social or social. In contrast, lesioned mice display intact
discrimination between a non-social and a social odor, which
are markedly different. A similar impairment has been observed
in mice overexpressing human α-synuclein, which discriminate
between strongly different scents, but lose gradually the abil-
ity to distinguish between citrus odors (Fleming et al., 2008).
Analogous olfactory defects have also been reported in transgenic
mouse models of dopamine dysfunction. For instance, a pro-
gressive age-dependent disruption of olfactory discrimination has
been reported in mice with reduced expression of the vescicular
monoamine transporter 2 (VMAT2) (Taylor et al., 2009), and
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in mice deficient for the dopamine transporter and the D2R
(Tillerson et al., 2006). Overall, the decrease in olfactory discrim-
ination observed in 6-OHDA-lesioned mice is in line with the
anosmia described in parkinsonian patients, which is character-
ized by a variable intensity and often manifested as lack of ability
to distinguish specific odors (Ward et al., 1983; Doty et al., 1988;
Mesholam et al., 1998; Braak and Del Tredici, 2009).
Our data show that a bilateral injection of 6-OHDA in the
striatum increases the immobility time in the forced swim test
and in the tail suspension test, two standard behavioral paradigms
indicative of depression. These findings are in line with previous
work performed in the 6-OHDA-lesioned rat (Winter et al., 2007;
Tadaiesky et al., 2008; Santiago et al., 2010; Drui et al., 2014); but
see (Eskow Jaunarajs et al., 2012).Moreover, increased immobility
in the forced swim and tail suspension tests have been described
in MPTP-lesioned mice and in mice with reduced expression of
VMAT2 (Mori et al., 2005; Fukui et al., 2007; Taylor et al., 2009).
In contrast, Branchi et al. (2010) did not observe any difference
in immobility time between sham and 6-OHDA-lesioned mice,
in the forced swim test. One possible explanation for this discrep-
ancy is that Branchi et al. utilized mice with a 43% depletion of
striatal dopamine, which is lower than that reported in the present
PD model (70%) (Bonito-Oliva et al., 2014). In addition, the two
studies used different stereotaxic coordinates for the 6-OHDA
injection, which may affect striatal territories distinctly inner-
vated by substantia nigra and ventral tegmental area. For instance,
in Branchi et al. striatal injections of 6-OHDA were performed
at a more rostral and medial level in comparison to the present
study, which targeted preferentially the dorsal-lateral striatum. It
is possible that these latter coordinates led to a more pronounced
depletion of dopamine in the substantia nigra. In this context,
it should be noted that the loss of nigro-striatal dopaminergic
neurons has been proposed to specifically mediate mood-related
disorders in experimental parkinsonism (Drui et al., 2014).
The depressive-like phenotype observed in our PD mouse
model was accompanied by increased thigmotaxis and reduced
time spent in the open arms of the elevated plus maze, which are
two standard behavioral parameters indicative of anxiety. These
results are in agreement with the frequent co-morbidity between
anxiety and depression observed in PD patients (Menza et al.,
1993) and with a number of observations in experimental mod-
els. In the rat, lesion with 6-OHDA has been reported to exert
anxiogenic-like effects (Tadaiesky et al., 2008; Chen et al., 2011);
but see (Branchi et al., 2008). In the mouse, lesion withMPTP did
not affect anxiety-related behavior (Vuckovic et al., 2008; Prediger
et al., 2010) and striatal injection with 6-OHDA was even found
to reduce anxiety in the elevated plus maze test (Branchi et al.,
2010). The present results are more in line with work performed
in VMAT2-depleted mice (Taylor et al., 2009) and indicate that
the combined manifestation of depression and anxiety can be
successfully modeled in a toxin-based mouse model of PD.
In this study we examined the ability of dopaminergic and
noradrenergic drugs to counteract the depressive- and anxiety-
like behaviors caused by the partial 6-OHDA lesion. The effi-
cacy of L-DOPA in treating affective disorders associated to
parkinsonism is currently debated, with data indicating that this
therapy is ineffective (Marsh and Markham, 1973; Kim et al.,
2009), or that it may even exacerbate some of these condi-
tions (Damasio et al., 1971; Choi et al., 2000). This situation is
reflected by similar inconclusive evidence from studies performed
in animal models. Thus, sub-chronic administration of L-DOPA
produced a partial improvement of the response of 6-OHDA-
lesioned rats in a learned helplessness paradigm of depression
(Winter et al., 2007), whereas chronic administration exacerbated
the anxiogenic-like effect of the lesion (Eskow Jaunarajs et al.,
2012). Our results indicate that repeated administration of L-
DOPA does not reverse the depressive- and anxiety-like behaviors
produced by partial bilateral lesion with 6-OHDA. In support of
these results, studies in rat and non-human primate models of PD
indicate that L-DOPA elicits an excessive efflux of dopamine from
non-dopaminergic neurons in areas such as the prefrontal cor-
tex and the hippocampus. This, in turn, could induce psychotic
states, which would reduce potential beneficial effects and even
exacerbate mood-related conditions (Eskow Jaunarajs et al., 2012;
Engeln et al., 2014).
The lack of efficacy of L-DOPA prompted the analysis of alter-
native dopaminergic treatments. In particular, we focused on
pramipexole, a D2R/D3R agonist, previously shown to reduce
mood-related symptoms in parkinsonian patients (Leentjens
et al., 2009; Barone et al., 2010). We found that treatment with
pramipexole effectively reverted the increase in immobility time
displayed by lesioned mice in the forced swim test, as well as
the anxiogenic-like effect produced by 6-OHDA in the elevated
plus maze test. These results indicate the reliability of the present
model and its predictive validity to study effective treatments for
psychiatric disorders associated to PD and refractory to standard
L-DOPA therapy.
One important question concerns the contribution of
dopamine and noradrenaline to the affective disorders observed
in PD. Clinical evidence indicates that selective blockers of
noradrenaline reuptake, such as reboxetine and desipramine,
ameliorate mood-related symptoms (Lemke, 2002; Devos et al.,
2008). It has also been proposed that noradrenergic fibers release
dopamine in the cerebral cortex (Devoto et al., 2005, 2008),
a finding which raises the question of the impact produced
on dopamine transmission by the loss of noradrenaline inner-
vation in brain regions primarily involved in depression and
anxiety. The 6-OHDA lesion utilized in this study affects both
dopamine and noradrenaline innervation (Bonito-Oliva et al.,
2014). Therefore, to assess the contribution of these systems to
mood-related conditions, we limited the lesion with 6-OHDA
to the dopamine neurons by pre-treating the mice with the
selective noradrenaline reuptake inhibitor, desipramine (Bonito-
Oliva et al., 2014). Interestingly, preserving the noradrenaline
innervation did not modify the depressive- and anxiogenic-like
effects of 6-OHDA. Thus, in the present PD model, a partial
loss of noradrenergic innervation, or a decrease of dopamine
release from noradrenergic terminals in cortical regions, appear
to have a negligible impact on affective dysfunctions. Notably,
we also found that administration of reboxetine counteracts both
depressive- and anxiety-like behaviors produced by the 6-OHDA
lesion. In light of the aforementioned results, it is unlikely that
these effects are exerted by promoting noradrenergic transmis-
sion. A more plausible explanation is that reboxetine acts by
Frontiers in Behavioral Neuroscience www.frontiersin.org August 2014 | Volume 8 | Article 290 | 9
Bonito-Oliva et al. Non-motor symptoms in experimental Parkinsonism
blocking dopamine uptake from noradrenaline terminals, which
is particularly efficient in extra-striatal regions, including cere-
bral cortex and hippocampus (Moron et al., 2002; Borgkvist et al.,
2012). Indeed, the partial effect exerted by 6-OHDA on TH neu-
rons in the locus coeruleus (Bonito-Oliva et al., 2014), indicates
that spared noradrenergic terminals may still be able to handle
dopamine in forebrain target areas.
In conclusion, the present study shows that a variety of
non-motor symptoms associated to PD can be reproduced in
a mouse model generated by a partial bilateral lesion with 6-
OHDA. In this model, subtle impairments of gait dynamics and
reduced olfactory discrimination, reminiscent of early stage PD,
are accompanied by depressive- and anxiety-like behaviors. These
affective dysfunctions are refractory to treatment with L-DOPA,
but reverted by the D2R/D3R agonist, pramipexole. Moreover,
they are counteracted by reboxetine, an inhibitor of noradrenaline
reuptake, but independent of the reduction of noradrenaline
transmission produced by the 6-OHDA lesion. Thus, the anti-
depressant and anxiolytic effects of reboxetine are most likely
exerted via blockade of dopamine reuptake from noradrenergic
fibers.
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